Related Experiment Video
Updated: Jun 4, 2026

Positron Emission Tomography Using 64-Copper as a Tracer for the Study of Copper-Related Disorders
Published on: April 28, 2023
Late diagnosed Wilson disease with hepatic and neurological manifestations
Yuichi Honma1, Masaru Harada, Miyuki Sato
1Third Department of Internal Medicine Department of Second Pathology and Cell Biology, University of Occupational and Environmental Health, Japan, School of Medicine, Kitakyushu Department of Gastroenterology, Social Insurance Tagawa Hospital, Tagawa, Japan.
Abstract:
A 50-year-old woman was referred to our hospital due to liver dysfunction and progressive neurological symptoms. She had previously been diagnosed with nonalcoholic steatohepatitis (NASH). Ursodeoxycholic acid (UDCA) had effectively normalized her serum aminotransferase levels, however, she presented with loss of balance, dysarthria and difficulty in handwriting. Autoantibodies and hepatitis virus markers were negative. Serum ceruloplasmin and copper levels were noted to be 9 mg/dL and 32 µg/dL, respectively. The 24-h urinary copper excretion was 331.8 µg/day. Kayser-Fleischer ring was demonstrated. Histological examination of the liver revealed inflammatory infiltrate and fibrosis, and the hepatic copper concentration was 444.4 µg/g dry weight. We diagnosed her as having Wilson disease and started treatment with trientine. Immuohistochemistry for keratin 8 and p62 demonstrated Mallory-Denk bodies. Many of the p62-expressing cells were positive for 4-Hydroxy-2-nonenal (HNE). Few Ki-67-positive hepatocytes were present in the liver. Wilson disease is one of the causes of NASH and UDCA may be a supportive therapeutic agent for Wilson disease. Cell proliferation is suppressed under copper-loaded conditions and this phenomenon may be associated with the clinical course of Wilson disease.
More Related Videos
05:12Portable Thermographic Screening for Detection of Acute Wallenberg's Syndrome
Published on: September 19, 2019
11:04Ion Mobility-Mass Spectrometry Techniques for Determining the Structure and Mechanisms of Metal Ion Recognition and Redox Activity of Metal Binding Oligopeptides
Published on: September 7, 2019
Related Concept Videos
Huntington Disease l: Introduction
Hepatic Encephalopathy
Multiple Sclerosis l: Introduction
Lysosomal Hydrolases
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Alzheimer Disease l: Introduction